At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAZE Maze Therapeutics
Post-Mkt 09-17 19:03:03 EDT
23.44
-0.47
-1.99%
盘后23.44
+0.000.00%
16:10 EDT
High24.80Low23.27Vol363.52K
Open24.38D1 Closing23.92Amplitude6.40%
Mkt Cap1.30BTradable Cap873.15MTotal Shares55.25M
T/O8.59MT/O Rate0.98%Tradable Shares37.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543
Reuters  ·  09-09
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543
Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65
Reuters  ·  09-04
Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
GlobeNewswire  ·  09-02
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75
Reuters  ·  09-01
Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75
Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
Dow Jones  ·  08-27
Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Reuters  ·  08-18
Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Reuters  ·  08-18
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Reuters  ·  08-15
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Reuters  ·  08-14
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Maze Therapeutics Announces Appointments to Its Board of Directors
THOMSON REUTERS  ·  08-14
Maze Therapeutics Announces Appointments to Its Board of Directors
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Reuters  ·  08-14
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
TIPRANKS  ·  08-13
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
Belite Bio Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-13
Belite Bio Q2 Net Loss Widens on Higher Expenses
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
TIPRANKS  ·  08-12
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Reuters  ·  08-12
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln
Reuters  ·  08-12
Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
TIPRANKS  ·  08-12
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG
Dow Jones  ·  08-12
Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG
Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Dow Jones  ·  08-12
Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Benzinga Earnings  ·  08-12
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Introduction

Company Name.
Maze Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--